Age and gender-specific reference intervals for a panel of lysophosphatidylcholines estimated by tandem mass spectrometry in dried blood spots

[1]  A. Moser,et al.  Newborn Screening for X-Linked Adrenoleukodystrophy: Past, Present, and Future , 2022, International journal of neonatal screening.

[2]  S. Sciortino,et al.  Adrenoleukodystrophy Newborn Screening in California Since 2016: Programmatic Outcomes and Follow-Up , 2021, International journal of neonatal screening.

[3]  H. Waterham,et al.  Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor , 2020, Frontiers in Cell and Developmental Biology.

[4]  Xiang Chen,et al.  The mechanisms of lysophosphatidylcholine in the development of diseases. , 2020, Life sciences.

[5]  Ying Zhuang,et al.  Evaluation of a panel of very long-chain lysophosphatidylcholines and acylcarnitines for screening of X-linked adrenoleukodystrophy in China. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[6]  A. Moser,et al.  X-linked Adrenoleukodystrophy: Pathology, Pathophysiology, Diagnostic Testing, Newborn Screening, and Therapies , 2019, International Journal of Developmental Neuroscience.

[7]  R. Christopher,et al.  Flow injection ionization-tandem mass spectrometry-based estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[8]  R. Ward,et al.  Pediatric Age Groups and Approach to Studies , 2019, Therapeutic innovation & regulatory science.

[9]  F. Parveen,et al.  An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases , 2019, International journal of molecular sciences.

[10]  G. Rizzo,et al.  Broadening the Spectrum of Adulthood X-Linked Adrenoleukodystrophy: A Report of Two Atypical Cases , 2019, Front. Neurol..

[11]  K. Ichihara,et al.  Reference intervals for 33 biochemical analytes in healthy Indian population: C-RIDL IFCC initiative , 2018, Clinical chemistry and laboratory medicine.

[12]  R. Christopher,et al.  Liquid chromatography-tandem mass spectrometry method for estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[13]  F. Eichler,et al.  The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration , 2018, The Journal of clinical endocrinology and metabolism.

[14]  M. Mearin,et al.  The impact of human breast milk components on the infant metabolism , 2018, PloS one.

[15]  R. Wanders,et al.  Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy. , 2017, Molecular genetics and metabolism.

[16]  A. Moser,et al.  Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots. , 2017, Molecular genetics and metabolism.

[17]  Y. Eto,et al.  Application of a diagnostic methodology by quantification of 26:0 lysophosphatidylcholine in dried blood spots for Japanese newborn screening of X-linked adrenoleukodystrophy , 2017, Molecular genetics and metabolism reports.

[18]  S. Ferdinandusse,et al.  Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders , 2017, Journal of Inherited Metabolic Disease.

[19]  P. Rinaldo,et al.  Simultaneous Testing for 6 Lysosomal Storage Disorders and X-Adrenoleukodystrophy in Dried Blood Spots by Tandem Mass Spectrometry. , 2016, Clinical chemistry.

[20]  T. Okuyama,et al.  A selective detection of lysophosphatidylcholine in dried blood spots for diagnosis of adrenoleukodystrophy by LC-MS/MS , 2016, Molecular genetics and metabolism reports.

[21]  R. Wanders,et al.  X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. , 2014, Brain : a journal of neurology.

[22]  G. Amidon,et al.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. , 2012, Clinical therapeutics.

[23]  V. D. De Jesús,et al.  Improved analysis of C26:0-lysophosphatidylcholine in dried-blood spots via negative ion mode HPLC-ESI-MS/MS for X-linked adrenoleukodystrophy newborn screening. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[24]  B. Poll-The,et al.  X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management , 2012, Orphanet Journal of Rare Diseases.

[25]  Denise Thomson,et al.  Standard 6: Age Groups for Pediatric Trials , 2012, Pediatrics.

[26]  A. Moser,et al.  Combined extraction of acyl carnitines and 26:0 lysophosphatidylcholine from dried blood spots: prospective newborn screening for X-linked adrenoleukodystrophy. , 2012, Molecular genetics and metabolism.

[27]  A. Moser,et al.  Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. , 2009, Molecular genetics and metabolism.

[28]  M. Matsuo,et al.  Blood Lysophosphatidylcholine (LPC) Levels and Characteristic Molecular Species in Neonates: Prolonged Low Blood LPC Levels in Very Low Birth Weight Infants , 2007, Pediatric Research.

[29]  Hugo Moser,et al.  Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings. , 2006, Molecular genetics and metabolism.

[30]  M. Matsuo,et al.  Quantification of lysophosphatidylcholines and phosphatidylcholines using liquid chromatography-tandem mass spectrometry in neonatal serum. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  A. Randolph,et al.  International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics* , 2005, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[32]  Kazuhiko Tanaka,et al.  Very Long‐Chain Fatty Acids in Erythrocyte Membrane Phospholipids in Adrenoleukodystrophy , 1989, Acta paediatrica Japonica : Overseas edition.

[33]  H. Nishio,et al.  A simple method to diagnose adrenoleukodystrophy using a dried blood spot on filter paper. , 1986, Clinica chimica acta; international journal of clinical chemistry.

[34]  V. D. De Jesús,et al.  Simultaneous quantitation of hexacosanoyl lysophosphatidylcholine, amino acids, acylcarnitines, and succinylacetone during FIA-ESI-MS/MS analysis of dried blood spot extracts for newborn screening. , 2016, Clinical biochemistry.

[35]  A. Moser,et al.  Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy. , 2015, Molecular genetics and metabolism.

[36]  A. Moser,et al.  Newborn screening for X-linked adrenoleukodystrophy: further evidence high throughput screening is feasible. , 2014, Molecular genetics and metabolism.